Canine demodicosis is a common inflammatory parasitic skin disease believed to be associated with a genetic or immunologic disorder. This disorder allows mites from the normal cutaneous biota to proliferate in the hair follicles and sebaceous glands, leading to alopecia, erythema, scaling, hair casting, pustules, furunculosis, and secondary infections.
Effective treatment of generalized demodicosis requires a systemic approach. In order to establish a prognosis and provide successful treatment, it is very important to evaluate the:
• General health of the dog.
• Predisposing or contributing factors.
• Age of onset.
• Extent and location of skin lesions.
• Presence of secondary infections.
BRAVECTO is the longest-lasting flea and tick protection, recently available in the veterinary market as flavored, chewable tablets, and labeled for the prevention and treatment of flea and tick infestations in dogs.
Fluralaner, the active principal of BRAVECTO, binds to the arthropod gamma-aminobutyric acid and glutamate receptor-regulated chloride channel and inhibits the arthropod nervous system, causing paralysis and death. IT has potent, fast, and long-lasting insecticide and acaricide effects, offering 12 weeks of protection.
Recently, BRAVECT has been suggested as an alternative efficacious treatment for canine demodicosis. The results of recent studies are encouraging because this new treatment modality offers the potential
to provide effective control of canine demodicosis with low administration frequency while helping prevent and control fleas and ticks, it is safe for use in breeding, pregnant, and lactating dogs, it is also safe for use in dogs with ABCB1-1 gene mutation, such as collies.
